



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

January 24, 2006

FILE COPY

Everett Carmody
SPEC Pharma
2329 Westlake Drive
Suite 5
Austin, Texas 78746

Dear Mr. Carmody:

Your petition requesting the Food and Drug Administration to refrain from approving any ANDA application for any generic version or other pharmaceutical alternative of Celestone Soluspan (brand of betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP), was received by this office on 01/23/2006. It was assigned docket number 2006P-0047/CP 1 and it was filed on 01/23/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management

2006 P-0047

ACK 1